TOP - May 2013, Vol 6, No 2

The following are a few abstracts of interest from the 54th Annual Meeting of the American Society of Hematology.

Studies have suggested that musculoskeletal toxicity associated with aromatase inhibitor therapy can lead to noncompliance in up to one-third of women with breast cancer.

Adverse effects (AEs) with regorafenib tend to occur early—during the first treatment cycle—and then quickly taper off.

Pharmacists can serve as an important information portal for access to investigational drugs through clinical trials or via expanded-access mechanisms.

In a head-to-head comparison for the treatment of metastatic renal cell carcinoma, pazopanib showed similar efficacy to sunitinib but was associated with fewer side effects and an increased quality of life, according to Robert Motzer, MD, of Memorial Sloan-Kettering Cancer Center, New York, who presented the COMPARZ trial at the European Society for Medical Oncology 2012 Congress, held in Vienna, Austria.

Jill Drury Awarded the TOP Pharmacist Award